Arena Pharmaceutical (NASDAQ:ARNA) shares traded 2.96% up during most recent session to reach at the closing price of $1.39. The stock exchanged hands 2.92 Million shares versus average trading capacity of 2.52 Million shares, yielding a market cap of $451.08 Million. Wall Street analysts covering the stock are projecting that the stock will reach $3.38 within the next 52-weeks. The mean target projections are based on 4 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Arena Pharmaceutical (NASDAQ:ARNA) high price target of $5 and with a conservative view have low price target of $2.

Leerink Swann “Initiates Coverage On” Arena Pharmaceutical (NASDAQ:ARNA) in a research note issued to investors on 5/19/17 to Outperform with price target of $5.

Additionally on 9/15/16 FBR Capital “Initiates Coverage on” Arena Pharmaceutical (NASDAQ:ARNA) to Outperform setting price target at $ and on 11/15/13 Wallachbeth “Initiates Coverage on” the stock to Buy at $9. Furthermore on 10/03/13 Cowen & Co. “Initiates Coverage on” the stock to Market Perform at $4.5.

On the other hand the company has Relative Strength Index (RSI 14) of 57.43 along with Average True Range (ATR 14) of 0.07, Consequently Arena Pharmaceutical (NASDAQ:ARNA)’s weekly and monthly volatility is 5.45%, 4.75% respectively. The company’s beta value is at 1.32.

In terms of Buy, Sell or Hold recommendations, Arena Pharmaceutical (NASDAQ:ARNA) has analysts’ mean recommendation of 2.4. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Arena Pharmaceutical (NASDAQ:ARNA)’s minimum EPS for the current quarter is at $-0.11 and can go high up to $-0.06. The consensus mean EPS for the current quarter is at $-0.08 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.11 earnings per share for the same quarter during last year.

Previously Arena Pharmaceutical (NASDAQ:ARNA) reported $-0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.07 by $-0.02. The company posted an earnings surprise of -28.6%.

Arena Pharmaceutical (NASDAQ:ARNA)’s revenue estimates for the current quarter are $5.43 Million according to 6 number of analysts, for the current quarter the company has high revenue estimates of $8.5 Million in contradiction of low revenue estimates of $3.1 Million. For the current year the company’s revenue estimates are $22.78 Million compared to low analyst estimates of $18.1 Million and high estimates of $32.1 Million according to 6 number of analysts.

Currently Arena Pharmaceutical (NASDAQ:ARNA)’s shares owned by insiders are 0.59%, whereas shares owned by institutional owners are 36%. However the six-month change in the insider ownership was recorded 4.08%, as well as three-month change in the institutional ownership was recorded -0.61%.

Arena Pharmaceutical (NASDAQ:ARNA) 52-week high price stands at $2.16 and low price stands at $1.13, its price distance from 52-week high is -35.65% while its distance from 52-week low price is 23.01%. The stock hit its 52-week high on 06/09/16, and 52-week low on 05/18/17.

Arena Pharmaceutical (NASDAQ:ARNA)’s trailing twelve month revenues are $120.8 Million, whereas its price to sales ratio for the same period is 3.73. Its book value per share for the most recent quarter is $0.11 while its price to book ratio for the same period is 12.64, as for as the company’s cash per share for the most recent quarter is $0.24, however its price to cash per share ratio for the same period is 5.67. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.